Perspective Therapeutics (NYSE:CATX) Price Target Cut to $17.00 by Analysts at Oppenheimer

Perspective Therapeutics (NYSE:CATX) had its price objective reduced by Oppenheimer from $19.00 to $17.00 in a research report sent to investors on Tuesday, Benzinga reports. They currently have an outperform rating on the stock.

Several other research analysts have also issued reports on CATX. Cantor Fitzgerald reiterated an overweight rating on shares of Perspective Therapeutics in a research note on Tuesday, June 25th. Lifesci Capital reissued an outperform rating on shares of Perspective Therapeutics in a report on Monday, May 6th. Royal Bank of Canada reaffirmed an outperform rating and set a $30.00 price objective on shares of Perspective Therapeutics in a research note on Friday, June 14th. Finally, Bank of America started coverage on shares of Perspective Therapeutics in a research note on Thursday, July 25th. They issued a buy rating and a $24.00 target price for the company. Seven research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of Buy and an average price target of $19.80.

Perspective Therapeutics Stock Performance

Shares of CATX opened at $13.43 on Tuesday. The company has a debt-to-equity ratio of 0.01, a current ratio of 12.98 and a quick ratio of 12.98. The business’s 50-day simple moving average is $11.91. Perspective Therapeutics has a 12 month low of $2.05 and a 12 month high of $19.05.

Perspective Therapeutics (NYSE:CATX) last issued its earnings results on Wednesday, May 15th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.10. The company had revenue of $0.33 million during the quarter. Analysts expect that Perspective Therapeutics will post -1.02 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Lori A. Woods purchased 4,587 shares of the firm’s stock in a transaction dated Friday, June 14th. The shares were acquired at an average cost of $10.90 per share, with a total value of $49,998.30. Following the completion of the purchase, the director now directly owns 159,985 shares of the company’s stock, valued at $1,743,836.50. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, CEO Johan M. Spoor acquired 10,000 shares of the company’s stock in a transaction on Thursday, June 13th. The stock was purchased at an average cost of $11.70 per share, with a total value of $117,000.00. Following the acquisition, the chief executive officer now owns 13,757 shares of the company’s stock, valued at approximately $160,956.90. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Lori A. Woods bought 4,587 shares of the business’s stock in a transaction on Friday, June 14th. The shares were acquired at an average price of $10.90 per share, for a total transaction of $49,998.30. Following the completion of the transaction, the director now owns 159,985 shares in the company, valued at approximately $1,743,836.50. The disclosure for this purchase can be found here. Over the last three months, insiders purchased 30,814 shares of company stock valued at $385,487. Insiders own 3.52% of the company’s stock.

Institutional Trading of Perspective Therapeutics

A number of hedge funds have recently modified their holdings of the company. Bank of New York Mellon Corp raised its holdings in Perspective Therapeutics by 214.0% in the second quarter. Bank of New York Mellon Corp now owns 137,268 shares of the company’s stock worth $1,369,000 after purchasing an additional 93,548 shares during the period. WINTON GROUP Ltd acquired a new stake in Perspective Therapeutics during the 2nd quarter worth $841,000. WealthPLAN Partners LLC bought a new position in Perspective Therapeutics during the second quarter worth about $1,695,000. ClariVest Asset Management LLC bought a new stake in Perspective Therapeutics in the 2nd quarter valued at approximately $540,000. Finally, Sykon Capital LLC boosted its position in Perspective Therapeutics by 4.7% during the 2nd quarter. Sykon Capital LLC now owns 37,932 shares of the company’s stock worth $378,000 after acquiring an additional 1,717 shares during the last quarter. 54.66% of the stock is currently owned by institutional investors and hedge funds.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.